后眼病市场：按产品、按应用、按地区 - 规模、份额、展望、机会分析，2022-2028 年

后眼部疾病泛指视网膜、脉络膜和视神经的疾病，主要包括青光眼、年龄相关性黄斑变性（AMD）和糖尿病视网膜病变（DR）。 治疗仪主要用于治疗眼后部疾病。

市场动态

眼后部疾病负担的增加、糖尿病患病率的增加、老年人口的增加、对安全有效治疗的需求增加、研究和开发活动的增加将导致全球成为预期推动眼病增长的主要因素市场。

例如，2021 年 12 月，AbbVie Inc.（Allergan）获得美国食品和药物管理局 (FDA) 的批准，将 1.25% 的 VUITY（盐酸毛果芸香碱滴眼液）用于治疗老花眼。现在药店可以通过处方购买.

此外，2020年6月，千住製药与大冢製药宣布在国内上市治疗青光眼和高眼压症的“艾拉胺复方眼药水”。

这项研究的主要特点

• 本报告对全球后眼疾病市场进行了深入分析，提供了以 2021 年为基准年的预测期 (2022-2028) 的市场规模和復合年增长率 (CAGR%)。我是这里。
• 它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
• 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
• 它根据以下参数（包括公司亮点、产品组合、主要亮点、财务业绩和战略）介绍了全球眼后部疾病市场的领先企业。
• 本研究涵盖的主要公司包括 Novartis AG、Merck & Co. Inc.、F. Hoffmann-La Roche AG、AbbVie Inc (Allergan)、Alcon Inc.、Bausch Health Companies Inc.、Aerie Pharmaceuticals、Santen Pharmaceutical Co. Ltd.、Second Sight Medical Products Inc.、Rainbow Medical Ltd (Nano Retina) 和 Regeneron Pharmaceuticals Inc.
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 本研究报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球眼后部疾病市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按产品分类
  • 市场概况：按应用分类
  • 市场概况：按地区
• 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

• 市场动态
  • 眼后节疾病负担增加
  • 严格的监管框架和政策
  • 对安全有效治疗的需求不断增长
• 影响分析
• 主要亮点
• 监管情景
• 产品发布和批准
• 害虫分析
• 对 PORTER 的分析
• 合併/收购场景

第 4 章后节段疾病的全球市场——冠状病毒 (COVID-19) 大流行的影响

• COVID-19 的流行病学
• 供应方和需求方分析
• 经济影响

第 5 章全球眼后节疾病市场：副产品，2017-2028

• 药物
• 设备

第 6 章。后节眼病的全球市场：按应用，2017-2028

• 黄斑变性
• 青光眼
• 糖尿病视网膜病变
• 其他用途

第 7 章按地区分列的后节段疾病全球市场，2017-2028

• 北美
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲
• 世界其他地方

第八章竞争格局

• Novartis AG
• Merck & Co. Inc.
• F. Hoffmann-La Roche AG
• AbbVie Inc（Allergan）
• Alcon Inc.
• Bausch Health Companies Inc.
• Aerie Pharmaceuticals
• Santen Pharmaceutical Co. Ltd.
• Second Sight Medical Products Inc.
• Rainbow Medical Ltd（Nano Retina）
• Regeneron Pharmaceuticals Inc.

第 9 章

• 调查方法
• 关于出版商

Posterior segment eye disease (PSED) is commonly defined as diseases of the retina, choroid & optic nerve and primarily include glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapeutic devices are primarily used in the treatment of the posterior segment eye disorders.

Market Dynamics:

Increase in burden of posterior segment eye disorders, increase in prevalence of diabetes, increase in geriatric population, rise in demand for safe and effective treatments, and increase in research and development activities are major factors expected to propel the growth of the global posterior segment eye disorders market over the forecast period.

For instance, in December 2021, AbbVie Inc. (Allergan) received the United States Food and Drug Administration (FDA) approval for VUITY (pilocarpine HCl ophthalmic solution) 1.25% to treat presbyopia and be available by prescription in pharmacies in the U.S.

Moreover, in June 2020, Senju Pharmaceutical and Otsuka Pharmaceuticals announced the launch of a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE Combination Ophthalmic Suspension, in Japan.

Key features of the study:

• This report provides in-depth analysis of the global posterior segment eye disorders market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global posterior segment eye disorders market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche AG, AbbVie Inc (Allergan), Alcon Inc., Bausch Health Companies Inc., Aerie Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Second Sight Medical Products Inc., Rainbow Medical Ltd (Nano Retina), and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global posterior segment eye disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global posterior segment eye disorders market.

Detailed Segmentation:

• Global Posterior Segment Eye Disorders Market, By Product:
  • Drugs
  • Devices
• Global Posterior Segment Eye Disorders Market, By Application:
  • Macular Degeneration
  • Glaucoma
  • Diabetic Retinopathy
  • Other Applications
• Global Posterior Segment Eye Disorders Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Novartis AG
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc (Allergan)
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Aerie Pharmaceuticals
  • Santen Pharmaceutical Co. Ltd.
  • Second Sight Medical Products Inc.
  • Rainbow Medical Ltd (Nano Retina)
  • Regeneron Pharmaceuticals Inc.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Application
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increase in burden of posterior segment eye disorders
  • Stringent regulatory framework or policies
  • Increase in demand for safe and effective treatment
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Posterior Segment Eye Disorders Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Posterior Segment Eye Disorders Market, By Product, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Posterior Segment Eye Disorders Market, By Application, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Macular Degeneration
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Glaucoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Diabetic Retinopathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Applications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Posterior Segment Eye Disorders Market, By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc (Allergan)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alcon Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aerie Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Santen Pharmaceutical Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Second Sight Medical Products Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rainbow Medical Ltd (Nano Retina)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us